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Abstract
The aim of this study was to investigate whether long-circulating liposomes can improve the anti-inflammatory activity of superoxide
dismutase (SOD). Small-sized poly(ethyleneglycol) (PEG)-liposomes containing SOD were prepared via different preparation protocols and
characterized in terms of encapsulation efficiency (EE), size, enzymatic activity and protein structure, to establish conditions where high EE
can be combined with preservation of enzyme activity and structure. It was observed that structural information from circular dichroism
analyses does not correlate with data on enzyme activity. SOD-containing PEG-liposomes prepared by the dehydration–rehydration method
appeared to represent the most attractive formulation for in vivo evaluation. The therapeutic potential of selected SOD-containing PEG-
liposomes was established and compared with SOD entrapped in stearylamine (SA)-liposomes and ‘free’ SOD upon intravenous (i.v.)
injection in an arthritic rat model. Both small PEG-liposomes and SA-liposomes showed a superior therapeutic activity compared to ‘free’
SOD, with PEG-liposomes inducing stronger anti-inflammatory effects than SA-liposomes. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
autoimmune disease that leads to damage of the articular
cartilage and subchondral bone [1]. Although the number of
drugs used in the treatment of RA has increased over the
past 10–20 years, there is still an urgent need for more
effective drugs with reduced side effects [1–3]. At present,
there is a revival of interest in the use of the antioxidant
enzyme superoxide dismutase (SOD) for clinical applica-
tions, in particular for the therapy of RA [4].
SOD has been proposed as a promising NSAID, as this
enzyme can protect against the damaging effects of reactive
oxygen species involved in this inflammatory joint disease
[3,5]. SOD is a cytoplasmic enzyme that dismutases the
superoxide radical in molecular oxygen and hydrogen per-
oxide, thus helping to protect cells against the toxic
byproducts of aerobic metabolism. SOD has been studied
for use in the treatment of several diseases in which the
superoxide radical is involved [3]. Because of its poor
pharmacokinetic profile [6], controlled delivery strategies
are desired. Among those, intravenously administered SOD-
containing liposomes were reported to be therapeutically
superior to the ‘free’ enzyme [7–9]. A maximum therapeu-
tic benefit of SOD is expected, if one would be able to target
SOD to its target sites, that is, inflamed tissues. A certain
0005-2736/02/$ - see front matter D 2002 Elsevier Science B.V. All rights reserved.
PII: S0005 -2736 (02 )00457 -1
Abbreviations: CD, circular dichroism; Chol, cholesterol; DSPE-PEG,
distearoylphosphatidylethanolamine-poly(ethyleneglycol) 2000; EE, encap-
sulation efficiency; E-PC, egg-phosphatidylcholine; F/T, multilamellar
liposomes obtained by the freeze– thawing method; IEP, isoelectric point;
Lip, total lipid; MLV, multilamellar liposomes; PEG, poly(ethyleneglycol);
PI, polydispersity index; Prot, protein; (Prot/Lip)i, initial protein-to-lipid
ratio; (Prot/Lip)f, final protein-to-lipid ratio; RA, rheumatoid arthritis; Ret.
Act., retained enzymatic activity; S.D., standard deviation; sDRV, multi-
lamellar liposomes prepared by the dehydration– rehydration method;
SOD, superoxide dismutase, [EC 1.15.1.1]
* Corresponding author. Tel.: +351-21-716-27-12; fax: +351-21-716-
36-36.
E-mail address: luisa.corvo@ineti.pt (M. Luisa Corvo).
www.bba-direct.com
Biochimica et Biophysica Acta 1564 (2002) 227–236
degree of target site accumulation can be achieved by
utilizing small ( < 0.15 Am), long-circulating liposomes that
are known to be able to escape from the circulation at
inflammation sites [10–12]. In rats, small liposomes bearing
poly(ethyleneglycol) (PEG) at their surface have circulation
half lives of over 24 h and indeed localize preferentially in
inflamed tissues [13,14]. Therefore, small-sized PEG-lip-
osomes were chosen in this study as preferred liposome type
for SOD targeting.
Up until now, hardly any efforts were made to optimize
the pharmaceutical characteristics of SOD-containing PEG-
liposomes. Therefore, we prepared small-sized SOD-con-
taining PEG-liposomes via different methods. Specific
attention was paid to issues of critical importance such as
maximizing encapsulation efficiency (EE) and preservation
of enzyme activity. Proper selection of the experimental
conditions could indeed substantially increase the EE with-
out loss of enzyme activity. These optimized SOD-contain-
ing PEG-liposome formulations were used for therapeutic
activity studies in vivo. A rat model of adjuvant arthritis was
used to investigate whether long-circulating liposomes offer
advantages over ‘conventional’ liposomes regarding the
anti-inflammatory activity of SOD. The results show that
long-circulating PEG-liposomes are superior to conven-
tional liposomes in enhancing SOD therapeutic activity in
rats with adjuvant arthritis.
2. Materials and methods
2.1. Chemicals
Egg-phosphatidylcholine (E-PC) was obtained from Lip-
oid, Ludwigshafen, FRG. Distearoylphosphatidylethanol-
amine-poly(ethyleneglycol) 2000 (DSPE-PEG) was
obtained from Avanti Polar Lipids, Alabaster, AL, USA.
Cholesterol (Chol), and bovine erythrocytes Cu,Zn–SOD
were purchased from Sigma, St. Louis, MO, USA. All other
chemicals were of reagent grade.
2.2. Animals
Male Wistar rats of more than 3 months in age and
weighing 450–500 g were obtained from Instituto Gulben-
kian de Cieˆncia, Oeiras, Portugal. Animals were fed with
standard laboratory food and water ad libitum. All animal
experiments were carried out with the permission of the
local animal ethical committee, and in accordance with the
Declaration of Helsinki.
2.3. Liposome preparation
Three different liposome preparation methods for the
encapsulation of SOD in long-circulating liposomes were
used. The aqueous phase consisted of an isotonic NaCl/
citrate buffer pH 5.6, unless otherwise stated.
2.3.1. Film hydration method, pH 5.6 [multilamellar
liposomes (MLV)]
MLV were prepared as follows: a mixture of the appro-
priate amounts of E-PC:Chol:DSPE-PEG in a molar ratio of
1.85:1:0.15 in chloroform was dried under a nitrogen stream
until a homogeneous film was formed. This film was
dispersed in a solution of 0.50 mg/ml SOD in 0.145 M
NaCl/10 mM citrate buffer pH 5.6 (lipid concentration = 16
Amol/ml).
2.3.2. Freeze–thawing method, pH 5.6 [multilamellar
liposomes obtained by the freeze-thawing method (F/T)]
F/T were prepared as follows: a mixture of the appro-
priate amounts of E-PC:Chol:DSPE-PEG in a molar ratio of
1.85:1:0.15 in chloroform was dried under a nitrogen stream
until a homogeneous film was formed. This film was
dispersed in a solution of 0.50 mg/ml SOD in 0.145 M
NaCl/10 mM citrate buffer pH 5.6 (lipid concentration = 16
Amol/ml). Five cycles of freezing in liquid nitrogen (5 min)
followed by thawing at 37 jC (5 min) concluded this
protocol.
2.3.3. Dehydration–rehydration method, pH 5.6 [multi-
lamellar liposomes prepared by the dehydration–rehydra-
tion method (sDRV)]
Multilamellar liposomes were prepared by the dehydra-
tion– rehydration method as previously described [9].
Briefly, a mixture of the appropriate amounts of E-
PC:Chol:DSPE-PEG in a molar ratio of 1.85:1:0.15 in
chloroform was dried under a nitrogen stream until a
homogeneous film was formed. This film was dispersed
in a solution of SOD (0.05–20 mg/ml) in water (lipid
concentration: 16, 32 or 48 Amol/ml), frozen in liquid
nitrogen and lyophilized overnight. Then, a 0.28 M man-
nitol/10 mM citrate buffer pH 5.6 was added to the
lyophilized powder up to 1/10 of the volume of the original
dispersion. This hydration step lasted 30 min, and, sub-
sequently, 0.145 M NaCl/10 mM citrate buffer pH 5.6 was
added to reach the starting volume. Except for the disper-
sions that were extruded (see below), nonencapsulated
protein was separated from the liposome dispersion by
dilution (26 times) and ultracentrifugation at 300,000 g
for 20 min at 4 jC in a Beckman LM-80 ultracentrifuge.
Finally, liposomes were dispersed in a 0.145 M NaCl/10
mM citrate buffer pH 5.6.
2.3.4. Extrusion method (Extrusion), pH 5.6
As a rule, liposomes obtained by the three previously
described methods were extruded sequentially through
polycarbonate filters with pore sizes of 0.6, 0.2, 0.10 or
0.05 Am. Nonencapsulated protein was separated from the
liposome dispersion by dilution (26 times) and ultracen-
trifugation at 300,000 g for 120 min at 4 jC in a
Beckman LM-80 ultracentrifuge. Finally, liposomes were
dispersed in a 0.145 M NaCl/10 mM citrate buffer pH
5.6.
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2.3.5. Dehydration–rehydration followed by extrusion; pH
4.0 or 3.3 (sDRV!Extrusion)
Liposomes were prepared as described above with the
following modifications: (1) for hydration of the lyophilized
powder to form liposomes, a 0.28 M mannitol/4 mM acetate
buffer with pH 4.0 or 3.3 was used. The volume of the
hydration buffer was 1/10 of the original dispersion volume;
(2) to reach initial volume of the dispersion, a buffer
consisting of 0.145 M NaCl/4 mM acetate buffer pH 4.0
or 3.3 was utilized; (3) after the separation of the non-
encapsulated protein by ultracentrifugation, liposomes were
dispersed in a 0.145 M NaCl/10 mM citrate buffer pH 5.6,
independently of the pH of the hydration buffer.
2.4. Preparation of SOD-liposomes for in vivo studies
For these studies, SOD-liposomes were prepared by the
dehydration–rehydration method, pH 5.6, followed by
sequential extrusion through polycarbonate filters ranging
from 0.6 to 0.2 Am or 0.05 Am in pore size. The lipid
concentration was 16 or 32 Amol lipid per milliliter hydra-
tion medium and the film was dispersed in a solution of
SOD (0.5–5 mg/ml). Nonencapsulated protein was sepa-
rated from the liposome dispersion by ultracentrifugation, at
300,000 g for 120 min at 4 jC in a Beckman LM-80
ultracentrifuge. Finally, liposomes were dispersed in 0.145
M NaCl/10 mM citrate buffer pH 5.6.
2.5. Circular dichroism (CD) studies
To monitor the secondary and tertiary structure of SOD in
aqueous media, CD spectra were run with a Jasco J-600 CD
spectropolarimeter (Japan Spectroscopic, Tokyo, Japan).
2.5.1. Secondary structure
Two milligrams per milliliter SOD solutions were pre-
pared in 10 mM phosphate buffer at pH 5.6 or 3.3 and in 33
mM H3PO4 at pH 1.5. When necessary, the pH was raised to
5.6 with 1 M NaOH. The reading conditions were: wave-
length range—260–190 nm, step resolution—0.1 nm, scan
speed—50 nm/min, time constant—0.125 s, band width—
1 nm.
2.5.2. Tertiary structure
Two milligrams per milliliter SOD solutions were pre-
pared in 10 mM phosphate buffer at pH 5.6 and 3.3. When
necessary, the pH was raised to 5.6 with 1 M NaOH. The
reading conditions were: wavelength range—350–250 nm,
step resolution—0.2 nm, scan speed—100 nm/min, time
constant—0.064 s, band width—1 nm.
2.6. Liposome characterization
Mean liposome size was determined by dynamic light
scattering with a Malvern 4700 system. As a measure of the
particle size distribution, the polydispersity index (PI) was
used. PI can range from 0 (monodisperse) to 1.0 (poly-
disperse).
Phospholipid concentration was determined according to
Fiske and Subbarow [15] as modified by King [16], or with
the Test-Combination Phospholipid Kit (Boehringer Man-
nheim).
2.7. Protein determination
Protein was determined with a modified Lowry method
[17] with prior disruption of liposomes with Triton X-100
and sodium dodecylsulphate [18]; ‘‘final protein’’ represents
total protein associated with liposomes after the removal of
the nonencapsulated protein.
2.8. SOD activity assay
The SOD enzymatic activity assay was based on the
ability of the enzyme to inhibit autoxidation of epinephrine
to adrenochrome at pH 10.2 [19,20]. In the case of deter-
mination of liposome-encapsulated enzyme, the enzyme
was first released from the liposomes by the addition of
20% Triton X-100 (yielding a dispersion containing 10%
Triton X-100). All activity measurements were performed
after dilution of the enzyme to a final concentration of 6 Ag/
ml at pH 5.6, 4.0 or 3.3 (yielding a dispersion containing
0.3% Triton X-100). Control experiments showed that this
procedure did not affect SOD activity.
Encapsulation efficiency
The EE was calculated as follows:
EE ¼ 100½ðProt=LipÞf=ðProt=LipÞi ð%Þ
where (Prot/Lip)i—initial protein-to-lipid ratio; (Prot/
Lip)f—protein-to-lipid ratio in the final liposomal disper-
sion; Prot—protein; Lip—lipid.
The retained enzymatic activity was defined as:
Ret: Act: ¼ ðFinal activity=Initial ActivityÞ100 ð%Þ
2.9. Animal experiments
2.9.1. Induction of the inflammation
Wistar rats were injected with a single intradermal
injection of 0.10–0.15 ml of a suspension of Mycobacte-
rium butiricum killed and dried (Difco) in incomplete
Freund’s Adjuvant (at 10 mg/ml), into the subplantar area
of the right hind paw [9]. The parameter of interest of
adjuvant-induced arthritis is the swelling of the paw, which
typically is established 7 days after the induction.
2.9.2. Treatment schedules
Treatments started at day 7 post-induction according to
one of the following schemes: (a) single dose–response
studies: intravenous (i.v.) tail-vein injection of a single dose
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of 33, 198 or 363 Ag SOD per rat on day 7 after the
induction; (b) multiple dose–response studies/injection fre-
quency effect: a dose of 33 Ag SOD per rat was given as (1)
one injection on day 7 (1 injection in total); (2) one injection
on days 7, 11 and 15 (3 injections in total); (3) one injection
on days 7, 9, 11, 13, 15 and 17 (6 injections in total); and (4)
one injection on days 7–17 (11 injections in total); (c)
multiple dose–response studies/dose effect: a daily i.v. tail-
vein dose was given for 11 days (days 7–17), the daily dose
was 66 Ag SOD per rat in the case of free SOD and 16, 33 or
66 Ag SOD per rat in the case of PEG-liposomes. Each
treatment group contained at least five rats. The paw oedema
was assessed by measurement of paw circumference [21].
SOD therapeutic activity was expressed as ‘‘percentage
oedema regression’’ calculated using the formula:
% oedema regression ¼ ðCat CbtÞ=ðCbi CbtÞ100 ð%Þ
where Cat = ankle circumference after the 11-day treatment
period (day 18); Cbt = ankle circumference before treatment,
7 days after induction (day 7); Cbi = ankle circumference
before the induction (day 0).
Fig. 1. Effect of (Prot/Lip)i on the (Prot/Lip)f during the extrusion process for the SOD PEG-liposomes. sDRV–non-extruded PEG-liposomes (.); sDRV–
PEG-liposomes extruded through a final pore size of 200 nm (n), sDRV–PEG-liposomes extruded through a final pore size of 100 nm (E), sDRV–PEG-
liposomes extruded through a final pore size of 50 nm (*). [Lip]i = 32 Amol/ml. Error bars represent standard deviation; n= 4.
Table 1
Initial lipid concentration [Lip]i and pH effect on the encapsulation
parameters of SOD in 110 nm PEG-liposomes
[Lip]i
(Amol/ml)
[Prot/Lip]i
(Ag/Amol)
[Prot/Lip]f
(Ag/Amol)
EE (%) Ret. Act.
(%)
pH 5.6 16 48F 2 4F 1 8F 2 > 95
32 24F 2 3F 1 13F 2 >95
48 15F 2 3F 1 21F 2 >95
pH 4.0 16 40F 2 5F 1 12F 1 70–75
pH 3.3 16 46F 2 14F 2 30F 2 50–55
32 24F 2 9F 2 36F 2 50–55
sDRV liposomes were prepared at the pH as indicated in the first column;
after extrusion, the pH of the aqueous phase was adjusted to pH 5.6.
[SOD] = 1.0 mg/ml. n= 4.
Table 2
pH effect on the SOD activity in the absence of liposomes and
encapsulation parameters for extruded SOD–PEGylated liposomes ex-
posed to two different pH conditions
pH Time (h) (Prot/Lip)i
(Ag/Amol)
EE (%) Ret. Act.
(%)
Size (Am)
5.6 4, 20 or 24 – – 95–100 –
3.3 4, 20 or 24 – – 25–30 –
3.3! 5.6 20 (pH 3.3) +
4 (pH 5.6)
– – 90–95 –
1.5 4, 20 or 24 – – < 1 –
1.5! 5.6 20 (pH 1.5) +
4 (pH 5.6)
– – 40–45 –
5.6! 3.3
! 5.6 – 42F 2 15F 1 90–95 0.11–0.12
5.6 – 42F 2 7F 1 90–95 0.11–0.12
n= 3. [SOD] = 1.0 mg/ml.
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2.10. Statistical analysis
All mean values are givenF standard deviation (S.D.).
Statistical analysis was performed using ANOVA test.
3. Results
3.1. Effect of preparation method on EE
SOD-liposomes were prepared at pH 5.6, as at this pH, no
loss of enzymatic activity and no structural changes of the
protein as detected by CD were observed. Three different
liposome preparation methods for the encapsulation of SOD
in long-circulating liposomes were studied: (1) the method
of film hydration followed by extrusion (MLV!Extrusion),
(2) the method of freeze–thawing followed by extrusion (F/
T!Extrusion) and (3) the method of dehydration–rehydra-
tion followed by extrusion (sDRV!Extrusion). For the
sDRV!Extrusion, the EE observed was more than twice
the EE observed for the MLV!Extrusion and the F/
T!Extrusion (9F 1%vs.3F 1%and4F 1%, respectively).
Similar results were obtained when calculating the final
protein-to-lipid ratio [(Prot/Lip)f] (14F 3 vs. 6F 1 and
6F 1 Ag/Amol, respectively). Thus, with the sDRV!Extru-
sion method, a larger fraction of added SOD can become
Fig. 2. CD spectra of Cu,Zn–SOD at different pH. (A) Secondary structure information: (a) [SOD] = 2.0 mg/ml, pH 5.6, (b) [SOD] = 2.0 mg/ml, pH 3.3, (c)
[SOD] = 2.0 mg/ml, pH 1.5, (d) [SOD] = 2.0 mg/ml, pH 1.5! 5.6 (solution c titrated from pH 1.5 to 5.6). (B) Tertiary structure information: (a) [SOD] = 2.0
mg/ml, pH 5.6, (b) [SOD] = 2.0 mg/ml, pH 3.3, (c) [SOD] = 1.5 mg/ml, pH 3.3! 5.6 (solution b titrated from pH 3.3 to 5.6).
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liposome ‘‘associated’’. For this reason, the sDRV!Extru-
sion method was the liposome preparation method of first
choice for further studies.
3.2. Effect of extrusion on size and final protein-to-lipid
ratio
As particle size affects the degree of localization of long-
circulating liposomes in inflamed tissue [10,13,14,22], the
effect of extrusion through membrane filters with decreasing
pore size on the final protein-to-lipid ratio was studied (Fig.
1). Extrusion through a final pore size of 0.2, 0.1 or 0.05 Am
resulted in liposomes with average sizes of 0.2, 0.14 or 0.11
Am, respectively. During the extrusion process, the content
of SOD in long-circulating liposomes dropped dramatically.
When the initial lipid concentration was increased, the final
protein-to-lipid ratio showed a slight tendency to drop, but
the EE increased almost linearly (Table 1).
3.3. Effect of pH on degree of SOD encapsulation,
enzymatic activity and protein structure
To prevent loss of SOD during the extrusion process
(Fig. 1), the effect of pH on SOD EE was studied. Decreas-
ing the pH below the isoelectric point (IEP) of the protein
(4.95), yielding a positively charged protein, was expected
to enhance the EE by increased interactions between SOD
and the liposome bilayers. By decreasing the pH from 5.6 to
3.0, the EE indeed increased from 8% to 30–35%, but,
unfortunately, the enzymatic activity dropped from 90% to
50% of the original activity (Table 1).
To find conditions where high EE is obtained while
enzyme activity and structure are preserved, a limited
number of studies were performed on the effect of pH on
the SOD activity in an aqueous milieu in the absence of
liposomes (Table 2). A pH drop from 5.6 to 3.3 resulted in a
loss of activity; enzyme activity could be fully recovered by
increasing the pH. However, in case of a pH drop to 1.5, no
full recovery of the SOD-activity was observed upon read-
justing the pH at pH 5.6.
The intention of the CD analyses was to provide guid-
ance in the selection process of the preferred SOD-liposome
formulation conditions. CD spectra were obtained to mon-
itor possible pH-dependent changes in the secondary and
tertiary structure of SOD in the absence of liposomes.
Structural changes might explain the observation of non-
recoverable activity of the enzyme at low pH. Secondary
structure data are shown in Fig. 2A. No differences were
observed in the secondary structure of the enzyme at pH 3.3
and 5.6. But, at pH 5.6, the enzymatic activity was 95%, and
Table 3
Characteristics of the SOD-liposomes studied
Lipid composition Molar ratio Mean sizea (Am) PIb Prot/Lipc (Ag/Amol)
SA-liposomes E-PC:Chol:SA 7:2:1 0.21F 0.01 < 0.20 12–15
PEG-liposomes E-PC:Chol:DSPE-PEG 1.85:1:0.15 0.11F 0.01 < 0.15 12–14
a MeanF S.D. of 25 dispersions.
b PI—polydispersity index.
c Prot/Lip—protein-to-lipid ratio.
Fig. 3. Anti-arthritic activity of free and liposomal SOD in a rat adjuvant
arthritis model: single dose– response relationship. Single dose tail vein i.v.
treatment was given on day 7 after arthritis induction. Control animals did
not receive any treatment. Treatment consisted of single i.v. doses (33, 198
and 363 Ag SOD per rat) of free SOD (A), SOD in SA-liposomes (B) and
SOD in PEG-liposomes (C). The number of animals per group was six; dots
represent the change in swelling of the inflamed paw induced by the
treatment (expressed as percentage oedema regression) assessed at day 18.
[—: mean value; (x): number of animals with the same oedema regression].
Negative values point to swelling increase during the observation period
starting on the first day of treatment (day 7) and ending at the day of
assessment (day 18). Positive values indicate swelling decrease during the
same observation period. *—Significantly different from the control group
( P < 0.05).
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at pH 3.3, it was only 25–30% of the reference (initial)
activity. At pH 1.5, a dramatic change was observed in CD
spectrum and the enzymatic activity was less than 1%.
However, when the same protein solution was titrated up
to pH 5.6, a complete recovery to the original secondary
structure was observed. Remarkably, SOD activity only
came back to 40–45% of the original level.
At the tertiary structure level, some changes in CD
spectra occurred at pH 3.3 as compared to SOD at pH 5.6
(Fig. 2B). These may be indicative for the loss of activity
upon pH decrease (see Table 2). When the pH of the protein
environment was readjusted at pH 5.6, a full recovery of the
enzymatic activity was obtained. Nevertheless, a change in
the CD spectrum compared to the original spectrum at pH
5.6 was observed.
Tables 1 and 2 provide conflicting results regarding
recovery of SOD activity upon pH changes. In Table 1,
there was no full recovery of SOD activity for SOD-lip-
osomes prepared by hydrating the sandwich SOD–lipid
structure at pH 3.3 and subsequently raising the pH to
5.6, while under exactly the same conditions, but in the
absence of liposomes, the protein fully recovered its activ-
ity. This finding was disappointing, because the higher SOD
EE at low pH was off set by the inactivation of the SOD due
to a change in the SOD structure. One might hypothesize
that this damage to the SOD structure might be the result of
a close, pH-dependent interaction between SOD and the
lipid bilayer during the hydration process. No structural
damage or loss of enzymatic activity might occur when lipid
hydration is performed at pH 5.6. To test this, sDRV
liposomes were hydrated at pH 5.6. Then, the pH was
lowered to pH 3.3 before the extrusion step and brought
back to pH 5.6 after extrusion. SOD EE and SOD activity
were compared with liposomes prepared at pH 5.6 where
the pH was kept constant during extrusion. Table 2 shows
the results. SOD EE was twice as high (15%) for the pH
5.6! 3.3! 5.6 liposomes as for the pH 5.6-liposomes
(7%) while the enzymatic activity level was still higher
than 90%. The protein was kept at pH 3.3 for 4 h; this
period of time is sufficiently long to reduce its activity
(Table 2). Readjusting the pH to 5.6 fully restores the
original intrinsic SOD activity. Thus, it is possible to
prepare small-sized SOD PEG-liposomes (0.11–0.12 Am)
with relatively high EE and full preservation of SOD
enzymatic activity.
3.4. Therapeutic activity in vivo
Two different SOD-liposome formulations were selected
for therapeutic activity studies. They are referred to as
stearylamine (SA)-liposomes (conventional liposomes) and
PEG-liposomes. The SA-liposomes were selected as they
already have been shown to be therapeutically active in the
rat model of adjuvant arthritis [9]. Lipid composition, size
and SOD loading characteristics are shown in Table 3. Both
liposome formulations show the same protein-to-lipid ratio,
to enable comparative in vivo studies at the same liposomal
lipid dose.
3.4.1. Single dose–response studies
Fig. 3 shows the anti-inflammatory activity of free SOD
and SOD encapsulated in both liposome types at escalating
single SOD doses (i.e. 33, 198 and 363 Ag of SOD per rat).
I.v. administration of the free enzyme did not result in
significant oedema regression, even at the highest dose
Fig. 4. Anti-arthritic activity of free and liposomal SOD in a rat adjuvant
arthritis model: effect of injection frequency. Treatment involved different
frequencies (four different schedules) of i.v. doses of 33 Ag SOD (per
injection) per rat of free SOD (A), SOD in SA-liposomes (B) or SOD in
PEG-liposomes (C): (1) one injection on day 7 (1 injection in total) (1 Inj);
(2) one injection on days 7, 11 and 15 (3 injections in total) (3 Inj), (3) one
injection on days 7, 9, 11, 13, 15 and 17 (6 injections in total) (6 Inj), and
(4) one injection on days 7–17 (11 injections in total) (11 Inj). Control
animals did not receive any treatment. The number of animals per group
was six; dots represent the change in swelling of the inflamed paw induced
by the treatment (expressed as percentage oedema regression) assessed at
day 18. [—: mean value; (x): number of animals with the same oedema
regression]. Negative values point to swelling increase during the
observation period starting on the first day of treatment (day 7) and ending
at the day of assessment (day 18). Positive values indicate swelling decrease
during the same observation period. *—Significantly different from the
control group ( P < 0.05). §—Significantly different from the 1 Inj group
( P< 0.05). #—Significantly different from free SOD ( P < 0.05).
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tested. In contrast, liposomally encapsulated SOD displayed
significant anti-inflammatory activity. At the lowest dose
level (i.e. 33 Ag SOD per rat), only the PEG-liposomes
showed significant activity (P < 0.05). At the two higher
dose levels (i.e. 198 and 363 Ag SOD per rat), both SOD-
liposome types showed significant activity (P < 0.05).
Increasing the SOD dose resulted in a significant improve-
ment of the anti-inflammatory activity only when SOD was
administered in the form of PEG-liposomes (P < 0.05) (Fig.
3). The mean oedema regression obtained at the 363-Ag
dose was 39% for the PEG-liposomes and 13% for the SA-
liposomes.
3.4.2. Multiple dose–response studies
To study the effect of injection frequency (Fig. 4), the
anti-inflammatory activity of free SOD and SOD in both
liposome types was evaluated at the dose level of 33 Ag
SOD (per injection) per rat in four different i.v. treatment
schedules: (1) one injection on day 7 (1 injection in total);
(2) one injection on days 7, 11 and 15 (3 injections in total);
(3) one injection on days 7, 9, 11, 13, 15 and 17 (6
injections in total); and (4) one injection on days 7–17
(11 injections in total).
For free SOD treatment (Fig. 4A), a slight but significant
activity was achieved only with the dose schedules involv-
ing 6 and 11 injections (P < 0.05). All treatment schedules
involving liposomal SOD (Fig. 4B and C) induced signifi-
cant anti-inflammatory activities (P < 0.05). In the case of
SOD in SA-liposomes (Fig. 4B), the 11-injection schedule
yielded a significantly improved therapeutic effect as com-
pared to the 1-injection schedule (P < 0.05). Remarkably, in
the case of SOD in PEG-liposomes (Fig. 4C), the 6-injection
schedule gave already a significant improvement as com-
pared to the 1-injection schedule (P < 0.05). When com-
pared to free SOD treatment, SA-liposomes yielded superior
anti-inflammatory effects only at the 11-injection schedule
while PEG-liposomes were more effective already at the 3-
injection schedule (P < 0.05). Whatever the treatment
schedule and SOD formulation, the swelling of the inflamed
paw did not increase during a 15-day period after termi-
nation of treatment.
Fig. 5 presents the anti-inflammatory effects of different
PEG-liposomal SOD doses (i.e. 16, 33 and 66 Ag SOD per
rat) at the 11-injection schedule. The results reveal that the
therapeutic activity of SOD in PEG-liposomes lacks dose
dependency over the dose range studied. These results are in
line with previous results obtained for the SA-liposomes
suggesting that further enhancement of the therapeutic
activity cannot be accomplished in this model by increasing
the liposomal SOD dose.
4. Discussion
Liposomes have attracted considerable attention for
increasing the short half-life of SOD and to target the
enzyme to the inflamed sites and thereby to increase its
anti-inflammatory activity [7,23–25]. It is striking that
studies reported up to now employed positively charged
liposomes containing SA as carriers of SOD. However, the
exact reason why SAwas used is obscure. In fact, the use of
positively charged SA-liposomes seems disadvantageous if
targeting of SOD to the site of inflammation is the goal, as is
the case in the present study. SA-liposomes can be expected
to be rapidly opsonized after i.v. administration with rapid
blood clearance and low uptake by the inflamed target as a
consequence. In recent years, it has been shown that
attaching PEG, conjugated to PE in the lipid bilayers,
considerably delayed and decreased the recognition of lip-
osomes by cells of the mononuclear phagocyte system
(MPS), mainly those located in the liver and spleen. As a
result, PEG-liposomes show an increased residence time in
the blood [26–28]. Previous studies demonstrate that the
prolonged residence time in the blood enables the PEG-
liposomes to localize preferentially at sites of enhanced
vascular permeability, for example, sites of arthritis
[10,13,14,22]. Therefore, PEG-liposomes ‘‘loaded’’ with
drugs can provide site-selective delivery of anti-rheumatic
agents. Previous studies did not show antigenicity of bovine
SOD at the doses used in rats [9]. No changes in biodis-
tribution and pharmacokinetics were observed as compared
to empty liposomes [13].
A variety of methods for the preparation of liposomes has
been described in the literature. The three preparation
approaches used in this paper to obtain SOD-liposomes
have a common denominator: the small chance of protein
damage because no organic solvents or detergent are in
contact with the protein and no sonication is used. Methods
involving organic solvents and/or sonication cannot be
applied to entrap SOD since they can inactivate the enzyme
Fig. 5. Anti-arthritic activity of free SOD and SOD in PEG-liposomes in a
rat adjuvant arthritis model: effect of dose. Treatment involved a daily i.v.
dose given for 11 days (days 7–17). The daily dose was 66 Ag SOD per rat
for free SOD and 16, 33 or 66 Ag SOD per rat for PEG-liposomes. Control
animals did not receive any treatment. The number of animals per group
was 6–14; points represent the change in swelling of the inflamed paw
induced by the treatment (expressed as percentage oedema regression)
assessed at day 18. [U: mean value; (x): number of animals with the same
oedema regression]. *—Significantly different from the control and free
SOD groups ( P < 0.05).
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[29]. The extrusion-sDRV method yielded the best results in
terms of EE. Indeed, this method has been described in the
literature to yield high EE with hydrophilic proteins [9,30].
This can be explained by the two-step procedure involving
(1) hydration of the protein–lipid sandwich lyophilized
mass obtained after dehydration with a relatively small
volume of buffer (without salts) followed by (2) adjustment
to the final volume in the second step [31].
However, after liposome formation, extrusion of the
hydrated sDRV is necessary to decrease liposome size, as
only small-sized long-circulating liposomes are known to
accumulate in inflamed sites. Unfortunately, extrusion leads
to a large decrease in EE (Fig. 1), the reason being that the
sDRV liposomes fracture during extrusion allowing SOD to
escape from the liposomal internal aqueous space (high
protein concentration) to the external phase (low protein
concentration). Table 1 shows that the protein concentration
gradient is still partly retained during extrusion as the EE for
SOD still exceeds the EE for the encapsulated water phase
[32–35]. A standard approach to prevent protein loss from
the liposomes is to charge the protein with a charge opposite
to the liposome bilayer. In this case, the DSPE-PEG
provides the bilayer with a negative charge (on the phos-
phate group). As the presence of PEG at the surface of
liposomes interferes with charge–charge interactions [36], it
was expected that this approach would fail to establish
sufficiently strong interactions between the protein and the
lipid bilayer. However, at pH 3.3, SOD is positively charged
(IEP= 4.95) and indeed appears to bind to the negatively
charged PEG-bilayer surface. Additional evidence for this
interaction was obtained by incubation of empty PEG-lip-
osomes with SOD at pH 3.3. Substantial binding of SOD to
the PEG bilayers was seen. The SOD–PEG bilayer inter-
action is pH dependent and decreases when the pH is
increased from 3.3 to 5.6 resulting in desorption of the
protein from the bilayer (data not shown). This pH effect on
SOD binding to liposomes was utilized to reduce SOD loss
during the extrusion process. Indeed, a higher EE of SOD
was obtained in the case of extrusion at pH 3.3, but,
unfortunately, a loss of enzymatic activity was also observed
(Table 1). In the absence of liposomes, there is a loss of
enzymatic activity at pH 3.3 and 1.5 (Table 2) compared to
pH 5.6. After increasing the pH from pH 1.5 or 3.3 to pH
5.6, this loss of SOD activity was reversible when starting
the pH increase at pH 3.3, whereas it turned out to be
irreversible when starting from pH 1.5. CD spectra did not
show permanent changes in the SOD secondary structure
when going through the pH cycle: 5.6 to 3.3 and back to 5.6
(Fig. 2) Interestingly, as far as tertiary structure is con-
cerned, some permanent changes were observed (Fig. 2).
Nevertheless, the enzymatic activity was completely
restored upon increasing the pH. This demonstrates that
information obtained by CD-spectroscopy does not neces-
sarily correlate with the enzyme activity data. An explan-
ation for this discrepancy (CD vs. activity) may be that the
tertiary structure changes are not immediately influencing
the active center of SOD. It should be kept in mind that the
tertiary structure changes may have an impact on other
characteristics of the molecule such as pharmacokinetic
profile or its immunogenicity (Table 2). Recovery of
enzyme activity upon pH increase does not happen in the
presence of liposomes prepared at pH 3.3 (Table 1). This
irreversible inactivation is probably due to changes in SOD
at the secondary level and/or loss of copper from the active
center due to lipid–protein interactions during hydration of
the SOD–lipid cake. This hypothesis is supported by the
observation that no loss of SOD activity occurs in the
presence of fully hydrated liposomes at pH 5.6 when the
pH is decreased to 3.3 only during the extrusion step.
The process for the preparation of SOD-containing PEG-
liposomes developed in this work yielded a relatively high
EE without loss of enzymatic activity. Therefore, we moved
forward toward therapeutic evaluation studies in the rat
adjuvant arthritis model. Rat adjuvant-induced arthritis is a
model of chronic polyarthritis with features that resemble
RA [21,37]. Previously, we have reported on the pharma-
cokinetics and biodistribution of PEG-liposomes in the rat
adjuvant arthritis model [14]. PEG-liposomes were clearly
superior to SA-liposomes in terms of localization at the
inflamed site, most likely as a result of their longer resi-
dence time in the bloodstream. The studies described herein
were designed to investigate whether the stronger targeting
capability of PEG-liposomes system can be translated into
an enhanced anti-inflammatory effect as compared to SA-
liposomes. The present results show that PEG-liposomes
indeed are superior to SA-liposomes in terms of anti-
inflammatory activity. In fact, at the single dose escalation
studies, improved activity due to liposome encapsulation
was observed only in the case of PEG-liposomes (Fig. 3).
Also, in the multiple dose–response studies, involving the
3-injection and 6-injection schedules, PEG-liposomes
induced stronger anti-inflammatory effects than SA-lipo-
somes (Fig. 4). Apparently, the stronger targeting capability
of PEG-liposomes as compared to SA-liposomes after i.v.
administration results in an enhanced anti-inflammatory
effect of the enzyme.
In conclusion, this report clearly shows how manipula-
tion of the preparation conditions can lead to increased EE
of active SOD. The process for the preparation of SOD
containing PEG-liposomes developed in this work yielded a
relatively high EE without loss of enzymatic activity. PEG-
liposomes are superior to SA-liposomes regarding enhance-
ment of the anti-inflammatory effect of SOD in rats with
adjuvant arthritis. We conclude that PEG-liposomes repre-
sent an attractive SOD delivery system, which should be
considered for clinical evaluation.
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